OncoMatch/Clinical Trials/NCT07725380
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Is NCT07725380 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Domatinostat and Sirolimus for sarcoma.
Treatment: Domatinostat · Sirolimus — This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Osteosarcoma
Demographics
Prior therapy
Must have received: systemic therapy
At least one prior standard systemic therapy regimen
Lab requirements
Blood counts
anc ≥1,000/mcl, platelets ≥100,000/ul, hemoglobin ≥8 g/dl
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
- Washington University in St. Louis · St Louis, Missouri
- Montefiore Medical Center · The Bronx, New York
- Nationwide Children's Hospital · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07725380 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Is there an age limit?
Yes. Patients must be 40 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages